review article | Q7318358 |
meta-analysis | Q815382 |
scholarly article | Q13442814 |
P50 | author | Douglas G. Altman | Q5300242 |
Dipak Kotecha | Q47805074 | ||
Andrew Coats | Q51710454 | ||
Gregory Lip | Q60393087 | ||
Dirk J van Veldhuisen | Q82060328 | ||
Henry Krum | Q82083581 | ||
Thomas von Lueder | Q91368281 | ||
Bert Andersson | Q92059050 | ||
Alan S Rigby | Q96051343 | ||
Giuseppe Rosano | Q96123790 | ||
Marcelo C Shibata | Q101152643 | ||
Paulus Kirchhof | Q38326091 | ||
John Cleland | Q44931654 | ||
P2093 | author name string | Milton Packer | |
Marcus D Flather | |||
Michael Böhm | |||
Hans Wedel | |||
John Wikstrand | |||
Jane Holmes | |||
Luis Manzano | |||
Peter D Collins | |||
P2860 | cites work | 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q22306358 |
Atrial fibrillation in heart failure: what should we do? | Q26784426 | ||
A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees | Q28238373 | ||
Angiotensin-neprilysin inhibition versus enalapril in heart failure | Q28247091 | ||
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) | Q28378044 | ||
Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design | Q30534526 | ||
Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study | Q30671950 | ||
??? | Q28267062 | ||
A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials | Q45002098 | ||
Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure | Q45002968 | ||
Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. | Q46184662 | ||
Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis | Q51354368 | ||
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group | Q72659033 | ||
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group | Q73073903 | ||
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure | Q73956766 | ||
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial | Q74452235 | ||
To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data | Q30676636 | ||
Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis | Q30847905 | ||
Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement | Q30940208 | ||
Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes | Q30981851 | ||
A comparison of methods for fixed effects meta-analysis of individual patient data with time to event outcomes | Q31137940 | ||
Empirical comparison of subgroup effects in conventional and individual patient data meta-analyses | Q31161606 | ||
Heart failure in women: a need for prospective data | Q33488753 | ||
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group | Q33893139 | ||
Effect of carvedilol on survival in severe chronic heart failure | Q33949292 | ||
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction | Q34187441 | ||
Gender Differences in Patients with Heart Failure | Q34277262 | ||
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). | Q34383304 | ||
Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction | Q34625223 | ||
Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction | Q34738402 | ||
Use of cardiovascular medications in the elderly | Q34809362 | ||
Gender and heart failure: a population perspective | Q35771154 | ||
Brief report: beta-blocker use among veterans with systolic heart failure | Q35901592 | ||
Trends and inequities in beta-blocker prescribing for heart failure. | Q36995236 | ||
beta-Adrenoceptor antagonists in elderly patients with heart failure: a critical review of their efficacy and tolerability | Q37004479 | ||
Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study | Q37102969 | ||
Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. | Q37285522 | ||
How to use a subgroup analysis: users' guide to the medical literature | Q38180653 | ||
Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes | Q38637232 | ||
Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21 864 patients in the Swedish Heart Failure Registry. | Q40248658 | ||
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group | Q42556789 | ||
Beta-blocker utilization and outcomes in patients receiving cardiac resynchronization therapy. | Q43022261 | ||
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial | Q43610373 | ||
Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). | Q43943294 | ||
Effect of gender on treatment, resource utilization, and outcomes in congestive heart failure in Quebec, Canada | Q44460258 | ||
Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial | Q44508242 | ||
Gender differences in advanced heart failure: insights from the BEST study | Q44697046 | ||
Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials | Q44872301 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | patient | Q181600 |
heart failure | Q181754 | ||
ejection fraction | Q641303 | ||
mechanism of action | Q3271540 | ||
heart failure with reduced ejection fraction | Q56218018 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | i1855 | |
P577 | publication date | 2016-04-20 | |
P1433 | published in | The BMJ | Q546003 |
P1476 | title | Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis | |
P478 | volume | 353 |
Q38654100 | A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial |
Q93068966 | Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry |
Q59767864 | B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data |
Q94517910 | Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment |
Q47776586 | Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials |
Q94337976 | Beta‐blockers for heart failure |
Q89072675 | Chronic heart failure |
Q90395738 | Contemporary Management of Heart Failure in the Elderly |
Q90753393 | Evolving towards a more realistic approach to the importance of left ventricular ejection fraction and sex in heart failure and its therapy |
Q47217070 | Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association |
Q39024144 | Heart failure management in the elderly - a public health challenge |
Q90678010 | Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF |
Q58804684 | Heart-brain Interactions in Heart Failure |
Q37536409 | Metoprolol Dose Equivalence in Adult Men and Women Based on Gender Differences: Pharmacokinetic Modeling and Simulations |
Q88711774 | Neurohormonal Blockade in Heart Failure |
Q90716759 | Risk factor-based subphenotyping of heart failure in the community |
Q60918058 | Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials |
Q92353984 | Saudi Heart Association (SHA) guidelines for the management of heart failure |
Q64954468 | Sex-Gender Variable: Methodological Recommendations for Increasing Scientific Value of Clinical Studies. |
Q90554320 | Sex-Specific Physiology and Cardiovascular Disease |
Q33880742 | Sex-specific mortality differences in heart failure patients with ischemia receiving cardiac resynchronization therapy |
Q38904292 | Summarising the Evidence for Drug Safety: A Methodological Discussion of Different Meta-Analysis Approaches. |
Q92452402 | The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared with the usual medical care for heart failure with reduced ejection fraction: A decision model-based analysis |
Q92327319 | Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come |
Q42850771 | β blockers for heart failure |
Search more.